   may cause drugdrug interactions for patients taking drugs to treat HIVAIDS or   according to a new statin warning from the FDA The agency singled out atorvastatin Lipitor rosuvastatin Crestor and simvastatin Zocor for the new warnings and restated a warning about mixing lovastatin Mevacor with HIV and HCV drugs Todays FDA safety communication follows label changes announced Tuesday that added cautions about new onset diabetes and transient memory problems for users of any of the   drugs in the statin class The FDA said that protease inhibitors taken with atorvastatin rosuvastatin simvastatin or lovastatin increase the concentration of statins in the blood which increases the risk for muscle injuries including risk for rhabdomyolysis which can cause permanent damage to the kidneys Specifically the agency said atorvastatin is contraindicated with a number of hepatitis C drugs and should be used with caution  at the lowest effective dose  among patients taking   Rosuvastatin should be limited to  mg daily in patients taking certain hepatitis C medications The FDA said simvastatin  like lovastatin  is contraindicated in patients taking HIV protease inhibitors boceprevir or telaprevir